Skip to main content

Multiple Sclerosis

Featured Article
Researchers recently presented long-term data assessing the safety and benefit-risk profile of ofatumumab for the treatment of relapsing multiple sclerosis.
“Costs associated with administering infusion DMDs among patients with MS in the US should be considered in economic analyses,” said researchers of a recent study.
Back to Top